Inhibition of proliferative vitreoretinopathy by a newly developed methotrexate loaded drug carrier in vitro.

Purpose: Repeated intravitreal injections of methotrexate for proliferative vitreoretinopathy, a rare ocular condition that can cause vision loss, have shown beneficial effects in recent clinical studies. The purpose of this study was to develop a slow-release, long-term drug carrier composed of the polymer polylactide-co-glycolide and methotrexate that can be injected intravitreally.

Methods: The required composition of the drug carrier was modeled using pharmacokinetic parameters based on current literature.